01—Abstract
Summary
Summary of the 8-K filed April 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Biogen reported first-quarter 2026 total revenue of $2.48 billiona, up 2% year-over-year as reported but down 2% at constant currency.
GAAP diluted EPS was $2.15b (up 31%) and non-GAAP diluted EPS was $3.57 (up 18%). Growth products rose 12%, led by LEQEMBI global in-market sales of $168 million (up 74%), ZURZUVAE (up 100%) and QALSODY (up 110%). The MS franchise was roughly flat, and SPINRAZA declined 12% on the timing of ex-U.S. shipments.
Q1 also benefited from roughly $40 millionc of favorable U.S. TYSABRI discount and allowance adjustments and $19 million of favorable ex-U.S. TYSABRI inventory timing. The headline news is the proposed acquisition of Apellis Pharmaceuticals, which Biogen expects to close in the second quarter of 2026 and which it says will be accretive in 2027 and materially lift non-GAAP EPS compound annual growth through the end of the decade. Biogen also agreed to acquire exclusive Greater China rights to felzartamab from TJ Biopharma.
Together these deals carry an approximately $1.00d per share acquired IPR&D charge, so full-year 2026 non-GAAP diluted EPS guidance was lowered to $14.25 to $15.25 from $15.25 to $16.25. The guidance excludes Apellis, and Biogen expects to issue a combined update with Q2 results. Full-year 2026 revenue is now expected to decline by a mid-single-digit percentage.
Balance sheet and cash flow remain solid. Operating cash flow was $646 million and free cash flow was $594 million.
Total debt was about $6.3 billion and net debt about $1.5 billion. Investors will want to track Apellis financing and closing conditions, the durability of growth-product momentum against MS erosion, and the pace of late-stage pipeline readouts for litifilimab and felzartamab.
02—Key points
Key Highlights
- Q1 2026 total revenue of $2,478 million rose 2% year-over-year as reported but declined 2% at constant currency; total product revenue fell 3% at constant currency.
- GAAP diluted EPS was $2.15 (up 31%) and non-GAAP diluted EPS was $3.57 (up 18%), helped by lower acquired IPR&D expense ($34 million versus $201 million a year earlier).
- Growth products grew 12% year-over-year, with LEQEMBI global in-market sales of $168 million (up 74%), ZURZUVAE $55 million (up 100%), SKYCLARYS $151 million (up 22%) and QALSODY $33 million (up 110%); SPINRAZA fell 12% to $374 million.
- Proposed Apellis Pharmaceuticals acquisition, expected to close in Q2 2026, adds immune-mediated retinal disease and nephrology medicines; Biogen expects it to be accretive in 2027.
- Full-year 2026 non-GAAP EPS guidance was cut to $14.25 to $15.25 from $15.25 to $16.25, reflecting an approximately $1.00 acquired IPR&D charge (about $0.20 in Q1 and $0.80 expected in Q2) and excluding Apellis.
- Full-year 2026 total revenue is expected to decline by a mid-single-digit percentage versus 2025, with declines in MS partly offset by growth products.
- Free cash flow was $594 million in Q1 and net debt was about $1.5 billion against roughly $6.3 billion of total debt at quarter end.
03—Questions
Frequently Asked Questions
Why did Biogen lower its 2026 EPS guidance if underlying results were strong?
The reduction is not an operating miss. Biogen lowered non-GAAP diluted EPS guidance by about $1.00 to reflect acquired IPR&D charges from business development activity: roughly $0.20 recorded in Q1 and about $0.80 expected in Q2. This includes about $0.55 from the felzartamab Greater China deal with TJ Biopharma and a $0.25 milestone expected in Q2. Biogen describes the charges as investment in growth, and the guidance excludes the Apellis transaction.
What is the Apellis deal and when will it affect results?
Biogen plans to acquire Apellis Pharmaceuticals, adding commercialized medicines in immune-mediated retinal disease and nephrology (the release names EMPAVELI and SYFOVRE). Closing is expected in Q2 2026, subject to customary conditions including regulatory approvals. Biogen expects the deal to be accretive in 2027 and to materially increase non-GAAP EPS compound annual growth through the end of the decade. Updated guidance including Apellis will come with Q2 2026 results.
Is the MS franchise still under pressure, and how much of Q1 was one-time?
MS product revenue was essentially flat at $958 million (down 3% at constant currency), and full-year 2026 revenue guidance assumes further MS declines excluding VUMERITY. Q1 MS results were supported by one-time or timing items, including about $40 million of favorable U.S. TYSABRI discount and allowance adjustments and about $19 million of ex-U.S. TYSABRI inventory timing. VUMERITY grew 29% partly on U.S. inventory dynamics, so underlying MS trends are weaker than the headline figures suggest.
How healthy is Biogen's balance sheet and cash generation to fund acquisitions?
Q1 operating cash flow was about $646 million and free cash flow was about $594 million. Biogen reported total debt of about $6.3 billion and net debt of about $1.5 billion at March 31, 2026, with cash and equivalents of roughly $4.7 billion per the release. The release does not detail how the Apellis acquisition will be financed, so investors should watch for financing disclosures around closing.
What pipeline catalysts did Biogen highlight?
Biogen cited a second positive Phase 2 CLE dataset for litifilimab showing meaningful reduction in disease activity at Week 16, which could make it the first targeted therapy for the disease if approved. It also reported additional Phase 1b salanersen data showing new motor milestones in children with SMA who had suboptimal responses to prior gene therapy. Felzartamab is described as a key Phase 3 kidney asset, and the SPINRAZA High Dose Regimen was approved in the U.S. Pipeline data are early or interim and remain subject to the risks in the forward-looking statements.
04—Continue